All In Biotech

Drug Trial Radar · NCT06431243

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

An Open, Multicenter Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Purinostat Mesylate for Injection in Combination Therapy for Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

May 8, 2024

Primary completion

May 1, 2026

Study completion Nov 1, 2026

Sponsor

Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives Phase Ib To evaluate the safety and tolerability of Purinostat Mesylate in combination therapy for advanced solid tumors; and to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of Purinostat Mesylate in combination therapy in patients with advanced solid tumors. To determine the recommended Phase II dose (RP2D) of Purinostat Mesylate in combination therapy for advanced solid tumors. Phase IIa To further evaluate the preliminary efficacy of Purinostat Mesylate in combination therapy in patients with advanced solid tumors. Secondary Objectives Phase Ib To evaluate the safety and tolerability of Purinostat Mesylate Monotherapy for the treatment of advanced solid tumors; To evaluate the preliminary efficacy of Purinostat Mesylate in combination therapy in patients with advanced solid tumors; To evaluate the pharmacokinetic characteristics of Purinostat Mesylate in combination therapy for the treatment of advanced solid tumors. Phase IIa To further evaluate the safety and tolerability of Purinostat Mesylate in combination therapy for advanced solid tumors. To evaluate the pharmacokinetic characteristics of Purinostat Mesylate in combination therapy for advanced solid tumors. Exploratory Objectives To assess the pharmacodynamic characteristics in Purinostat Mesylate combination therapy for advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • A0/B0 group Purinostat Mesylate 11.2mg/m2Drug

    Purinostat Mesylate 11.2mg/m2

  • A0/B0 group Purinostat Mesylate 15mg/m2Drug

    Purinostat Mesylate 15mg/m2

  • A group Purinostat Mesylate 6mg/m2Drug

    Purinostat Mesylate 6mg/m2 + FS 500mg

  • A group Purinostat Mesylate 8.4mg/m2Drug

    Purinostat Mesylate 8.4mg/m2 + FS 500mg

  • A group Purinostat Mesylate 11.2mg/m2Drug

    Purinostat Mesylate 11.2mg/m2 + FS 500mg

  • A group Purinostat Mesylate 15 mg/m2Drug

    Purinostat Mesylate 15 mg/m2 + FS 500mg

  • B group Purinostat Mesylate 6 mg/m2Drug

    Purinostat Mesylate 6mg/m2 + Tislelizumab 200mg

  • B group Purinostat Mesylate 8.4 mg/m2Drug

    Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg

  • B group Purinostat Mesylate 11.2mg/m2Drug

    Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg

  • B group Purinostat Mesylate 15mg/m2Drug

    Purinostat Mesylate 15mg/m2 + Tislelizumab 200mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rate (ORR)Time frame: Up to week 96

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guanzhou, Guangzhou, China · Recruiting

  • West China hospital of Sichuan university

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.